These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36034031)

  • 1. Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report.
    Badheeb A; Alkhanbashi O; Rakrouki S; Mahmood T; Alqannas M; Badheeb M; Ahmed F
    Pan Afr Med J; 2022; 42():98. PubMed ID: 36034031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ileal perforation in the setting of atezolizumab immunotherapy for advanced bladder cancer.
    Zillioux J; DiLizia M; Schaheen B; Rustin R; Krupski TL
    Can J Urol; 2018 Oct; 25(5):9525-9526. PubMed ID: 30281011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
    Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
    Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
    Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
    Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
    Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    Lavoie JM; Bidnur S; Black PC; Eigl BJ
    Urology; 2017 Aug; 106():1-2. PubMed ID: 28454987
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.
    Tree AC; Jones K; Hafeez S; Sharabiani MTA; Harrington KJ; Lalondrelle S; Ahmed M; Huddart RA
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1168-1171. PubMed ID: 30012528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
    Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer.
    Singh B; Kaur P; Gupta S; Guragai N; Maroules M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211035603. PubMed ID: 34308703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
    Hunter L; Moser J; Sturge C; Barraza G; Colonna S
    J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
    Hellman JB; Traynis I; Lin LK
    Orbit; 2019 Jun; 38(3):244-247. PubMed ID: 29985683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
    Fukushima H; Kijima T; Fukuda S; Moriyama S; Uehara S; Yasuda Y; Tanaka H; Yoshida S; Yokoyama M; Matsuoka Y; Saito K; Matsubara N; Numao N; Sakai Y; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
    Cancer Med; 2020 Nov; 9(22):8355-8363. PubMed ID: 32886446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review.
    Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K
    J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.